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Background: Pain is common in people with dementia, yet identification is challenging. A number of pain assessment
tools exist, utilizing observation of pain-related behaviours, vocalizations and facial expressions. Whilst they have been
developed robustly, these often lack sufficient evidence of psychometric properties, like reliability, face and construct
validity, responsiveness and usability, and are not internationally implemented. The EU-COST initiative ? Pain in impaired
cognition, especially dementia? aims to combine the expertise of clinicians and researchers to address this important
issue by building on previous research in the area, identifying existing pain assessment tools for dementia, and
developing consensus for items for a new universal meta-tool for use in research and clinical settings. This paper
reports on the initial phase of this collaboration task.
Methods: All existing observational pain behaviour tools were identified and elements categorised using a three-step
reduction process. Selection and refinement of items for the draft Pain Assessment in Impaired Cognition (PAIC)
meta-tool was achieved through scrutiny of the evidence, consensus of expert opinion, frequency of use and
alignment with the American Geriatric Society guidelines. The main aim of this process was to identify key items
with potential empirical, rather than theoretical value to take forward for testing.
Results: 12 eligible assessment tools were identified, and pain items categorised according to behaviour, facial expression
and vocalisation according to the AGS guidelines (Domains 1 ? 3). This has been refined to create the PAIC meta-tool for
validation and further refinement. A decision was made to create a supporting comprehensive toolkit to support the core
assessment tool to provide additional resources for the assessment of overlapping symptoms in dementia, including AGS
domains four to six, identification of specific types of pain and assessment of duration and location of pain.
Conclusions: This multidisciplinary, cross-cultural initiative has created a draft meta-tool for capturing pain behaviour
to be used across languages and culture, based on the most promising items used in existing tools. The draft PAIC
meta-tool will now be taken forward for evaluation according to COSMIN guidelines and the EU-COST protocol in
order to exclude invalid items, refine included items and optimise the meta-tool.
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There are an estimated 35.6 million people with demen-
tia worldwide and this figure continues to rise [1]. The
condition represents a significant public health issue, yet
treatment and care often fall below basic standards due
to the unique and complex challenges presented by
dementia. Identification and assessment of pain in
people with dementia present a particular challenge. It is
thought that up to 80% of people with dementia living in
care homes regularly experience pain [2]. However, there
is conflicting evidence regarding the incidence of pain in
people with dementia. A number of studies have reported
lower prevalence of pain in these individuals compared to
healthy older adults, although it is also likely that pain is
under-reported due to the difficulties experienced by
health care professionals in detecting it [3,4]. There is
some limited evidence for altered pain pathways as a
result of the pathology associated with dementia which
includes degeneration of pain centres in the medial pain
system [5,6]. Some studies have also reported an increased
threshold of pain tolerance in people with Alzheimer ? s
disease (AD) [7]. However this evidence is conflicting,
with other studies reporting no alteration or increases in
pain processing in AD as measured through EEG, fMRI,
psychophysical and observational measures [8]. As yet the
detection of pain through these approaches is imperfect
and this should be taken into account when interpreting
these studies.
Pain in dementia is usually related to musculoskeletal,
gastro-intestinal and cardiac conditions, genito-urinary
infections, pressure ulcers and oral pain. Neuropathic
pain, defined as pain caused by a lesion or dysfunction
in the central nervous system, is common in dementia.
This is particularly the case in people with vascular
dementia (VaD) due to the high prevalence of diabetes,
and stroke in this group, leading to deafferentiation, a
form of central neuropathic pain caused by white matter
lesions [9,10]. Approximately 35% of stroke patients are
known to suffer from post-stroke central neuropathic
pain [11]. Furthermore, Scherder et al. recently sug-
gested that central neuropathic pain is by far the most
undertreated type of pain in patients with dementia [12].
Despite these numerous established causes of pain,
international epidemiological research has reported that
the use of pain medication is often inappropriate in this
patient group [7]. This is particularly prominent in care
home and hospital settings where people are likely to
have more severe cognitive impairment and are reliant
on prescription of analgesics by health professionals. A
large number of studies have emphasised the challenge
of assessing pain in people with dementia in these set-
tings, and it is likely that this is the primary contributing
factor to under-treatment of pain in these individuals
[7,13].Thorough assessment of pain is essential to ensure
effective treatment and ongoing care. In most patient
groups the most effective method of identifying pain is
through self-report. However, a key symptom of dementia
is the loss of ability to communicate, particularly in the
later stages of the condition. In addition, these people
often lack insight into their condition. These factors com-
bined mean that people with dementia do not have the
ability to give an accurate report of their pain, its duration,
location and severity. As a result the majority of general
pain assessment tools are often partially inappropriate for
use in dementia. A key element of any assessment tool for
dementia would be the observation of pain-related behav-
iours as substitutes for verbal reports of pain, especially in
moderate and severe dementia, to detect the presence and
intensity of pain by a trained observer. In addition, in
order to provide a full picture of the pain an ideal tool
would also enable assessment of the location and duration
of pain through extended observation of the individual.
Differentiation of pain states varies in complexity. Whilst
spontaneous, acute pain, for example after a fall, is rela-
tively easy to identify through the resulting facial, verbal,
and behavioural pain indicators, chronic pain is more dif-
ficult to detect, requiring identification of more indirect
pain avoidance behaviours such as reduced movement or
apathy. Musculoskeletal pain can often be identified
through monitoring responses to guided movements
whilst visceral and neuropathic pains are more challenging
to detect [14]. Oral pain is also particularly dominant in
this patient group, yet no existing pain assessment tools
include oral pain as a key factor. A recent review identified
this need, and highlighted the inclusion of pain-related
items such as modified oral movement and behaviours as
key to a comprehensive tool [15]. An ideal pain assess-
ment tool would capture a combination of all these
aspects to provide a broad view of the pain experienced by
an individual at one point in time. It should be noted
however that the subjective experience of pain and the
complexity of the issue, particularly in a patient group
where comorbidities and communication impairments are
common, makes the development of such a perfect tool
extremely unlikely. Therefore, the most important object-
ive of a pain assessment tool must be to enable detection
of pain and its approximate intensity to enable further
examination and appropriate treatment and to monitor
the effects of treatment.
In 2002 the American Geriatric Society (AGS) published
guidance which provides a useful framework for develop-
ing an assessment tool for pain in dementia (Table 1) [16].
A number of observational and informant-based assess-
ment tools have been developed based on identification of
specific behaviours, many of which align closely with the
AGS guidelines. The tools are applied by a proxy rater,
usually a caregiver (health professional or family carer)
Table 1 Common Pain Behaviours in Cognitively Impaired
Elderly Persons according to the AGS Panel on Persistent
Pain in Older Persons [16]
Domain Items
1: Facial expressions Slight frown/sad or frightened
expression
Grimacing, wrinkled forehead,
closed or tightened eyes
Any distorted expression
Rapid blinking
2: Verbalisations & vocalisations Sighing, moaning, groaning
Grunting, chanting, calling out
Noisy breathing
Asking for help
Verbally abusive
3: Body movements Rigid, tense body posture,
guarding
Fidgeting
Increased pacing, rocking
Restricted movement
Gait or mobility changes
4: Changes in interpersonal
interactions
Aggressive, combative,
resisting care
Decreased social interactions
Socially inappropriate, disruptive
Withdrawn
5: Changes in activity patterns
or routines
Refusing food, appetite change
Increase in rest periods
Sleep, rest pattern changes
Sudden cessation of
common routines
Increased wandering
6 Mental status changes Crying or tears
Increased confusion
Irritability or distress
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tion of behaviours, emotions, interactions and facial ex-
pressions. A number of systematic reviews have examined
the range of tools currently available for use in dementia.
One recent review concludes that there are 12 promising
pain assessment tools instruments available, but the ma-
jority of these require further validation in people with de-
mentia and for day-to-day use in clinical settings [7].
Whilst many of the available tools have been developed
through robust methodology, including intensive observa-
tion in the clinic, consultation with users and patients,
and refinement of items, the existing tools are disparate,
with no one universal tool. In particular, whilst there is
some agreement between existing tools on the concepts
for pain assessment, there is great disparity in the methodsby which they are operationalized. Importantly, existing
tools frequently lack comprehensive data on face and con-
struct validity, reliability and responsiveness. Few dictate
the specific situation in which assessment should take
place, for example during rest, guided movement or dur-
ing daily activities, nor have the majority been developed
for ease of use in clinical settings and clinical utility. As a
result, no truly universal tool for detection of pain in
dementia exists. There remains an urgent need to draw on
the currently available resources and to develop an easy-
to-use assessment tool which has utility in both research
and clinical settings, and robust validation data to support
its implementation.
A major problem in the development of pain assessment
tools is that the scope of distinct pain-related behaviours
is difficult to distinguish from other behavioural symp-
toms that commonly arise in people with dementia. These
individuals frequently develop symptoms such as agita-
tion, aggression and apathy, collectively described as the
Behavioural and Psychological Symptoms of Dementia
(BPSD). 90% of people with dementia experience BPSD at
some point in their condition, and this is most common
in the more severe stages of their impairment. The under-
lying causes of BPSD are varied and complex. Pain is a
major contributor, and any comprehensive pain assess-
ment tool must consider and include BPSD to ensure
these factors are identified and included in a diagnosis.
There is emerging evidence indicating that verbal agitation
behaviours such as complaining, negativism, repetitious
sentences and questions, constant request for attention,
and cursing or verbal aggression respond to pain treat-
ment. In addition, certain BPSD such as restlessness and
pacing have been shown to be sensitive to treatment with
analgesics [17]. However, the definition of true pain-
related behaviours is vague, and varies widely between
individuals. This complication is likely to lead to incorrect
detection of pain or and inaccurate diagnosis of BPSD due
to the underlying causative pain. This inaccuracy in diag-
nosis can result in inappropriate treatment, including the
use of antipsychotic medications to address BPSD un-
necessarily. Conversely, people may be treated with analge-
sics under the assumption of underlying pain in the
absence of a meaningful assessment, and receive analgesia
without due cause. A valid pain assessment tool must
therefore consider the importance of both specific and
non-specific pain indicators to enable first detection of
pain and then differential diagnosis of the underlying cause
in order to support appropriate treatment and care.
The EU-COST action ? Pain in impaired cognition, espe-
cially dementia? was initiated in 2011 and currently
includes representatives from 16 European nations. It is a
four-year initiative which aims to draw on the combined
clinical, research and methodological expertise of its
members which include nurses, geriatricians, psychiatrists,
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physiotherapists, palliative care experts and experts in
clinimetrics, in addition to physiological/experimental
(human and animal) researchers. The group also includes
a number of authors of previous pain assessment tools.
The COST action is coordinated by a central Management
Committee. Five Working Groups (Psychometrics and
Algesimetry, Nursing and Care, Clinical Evaluation and
Epidemiology, Experimental Evaluation and Palliative
Care) have been created to oversee specific areas, all of
which are integrated with representative members and
cross-working to ensure effective collaboration. The pri-
mary aim of the collaboration is to establish the current
situation of pain assessment in dementia and to develop
and evaluate a comprehensive international tool for use in
both clinical and research settings. Key elements of the
proposed tool are summarised in Table 2. The multidis-
ciplinary, cross-cultural approach will allow for a novel
? joined-up? approach to development and evaluation,
incorporating international contributions and expertise
throughout the process from all key stakeholder groups.
The decision to create a meta-tool based on existing
instruments was informed by a thorough review of the
literature and current clinical practice which revealed the
absence of a single tool for use in all settings which is
embedded in the practicalities of clinical practice and
user-based design. The initiative aims to develop a truly
unique meta-tool which, instead of being developed fromTable 2 Key elements of the proposed PAIC tool and toolkit
Theme Required element
Process ? Makes use of the best items from existing instruments,
developing a meta-tool with a pool of useful items
? To provide a toolkit, not a single tool, out of which
instruments can be created for different contexts of
application (type of cognitive impairment, setting etc.)
? Provide potential to create specific tools (or additional scales)
for specific pain associated conditions (such as oral-facial
pain, back pain, neuropathic pain)
? Includes a guideline-and web-based, multilingual application
? Instruments for use in both clinical practice and research
? Creation and validation of instruments follows a predefined
process, following the COSMIN* criteria.
Quality ? Practicable and feasible in different settings (home care,
long term care, palliative care and acute hospital care) and
different countries (with first the focus on the Western world)
? Sound psychometric properties, i.e. a reliable and
valid instrument
? Sensitive to change, i.e. identify new pain and detect
changes after successful intervention, for instance with
pain medication
? Feasible and valid in several important groups of people
with cognitive impairment, such as dementias, coma/pvs
and people with a mental handicap or learning disability.
*COSMIN: COnsensus-based Standards for the selection of health
Measurement [18].patient observations, is based on the scrutiny and inclusion
of items from existing assessment tools based on empirical
evaluation of each item. This innovative approach ensures
the best, most informative are used. Furthermore, the
meta-tool will form part of a more comprehensive toolkit
which will provide supporting resources and guidance to
capture the nuances of pain in dementia including the spe-
cific needs of assessing pain in different locations and set-
tings, and to support decision-making regarding the most
suitable treatment. This will also support assessment in
distinct patient groups including Parkinson? s Disease De-
mentia, Huntington? s disease and delirium. Thorough
evaluation of the meta-tool and the associated toolkit will
conform to the newest international criteria for develop-
ment and testing of measurement instruments, as have
been described by the international COSMIN group [18].
This paper describes the first phase of the EU-COST ac-
tion programme of research which incorporates a thorough
review of existing assessment tools for pain in dementia
and the systematic evaluation of individual elements to cre-
ate an initial draft meta-tool for further evaluation.
Methods
Search strategy
A systematic search of the PubMed (N = 186), EMBASE
(N = 143) and Cochrane (N = 11) databases was conducted
to identify reviews of pain assessment tools published be-
tween 2005 and 2011. An updated search was conducted
in September 2012 using the same criteria. The search
was conducted in collaboration with the library at the
University of Bergen, Norway. The following search terms
were used: ? dementia? OR ? Alzheimer`s disease? , AND
? pain? , ? aggression? , ? neuropsychiatric? , ? pain prevalence? ,
? pain diagnoses? , ? pain assessment? , ? pain assessment
instruments? , ? pain assessment recommendation? , ? pain
behaviour? , ? management? , ? treatment? , ? analgesics? and
the names of individual and non-pharmacological treat-
ments AND ? nursing home? , ? treatment recommendation? ,
? review? , ? randomized clinical trial? .
Inclusion of pain assessment tools
Pain assessment tools included in this review had been
published as measures and recommended in review arti-
cles between 2005 and 2011. The tools were available on-
line or through a published article, and had been reported
as useful in clinical practice for patients with dementia.
Priority was placed on tools with available published data
for reliability, face validity and sensitivity to change,
although such evidence was limited. Furthermore, tools
were selected with some indication of feasibility for use in
various settings (home care, long term care, palliative care
and acute hospital care) and different countries, with first
the focus on the Western world, sound psychometric
properties, and good psychometric properties in more
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ent types of dementia, coma or people with a learning
disability. Flexibility in eligibility criteria was allowed to
account for the different levels of supporting evidence.
Fulfilment of eligibility criteria was confirmed through an
expert consensus process including an expert panel
consisting of members of the Working Groups in the EU-
COST action. This rigorous selection approach ensured
that the process resulted in the best possible pool of pain
assessment items with which to create the new tool.Expert panel
The review and refinement strategy was led by a series of
expert panels unique to COST Action TD 1005. Psycho-
metric scale development was primarily performed by the
Psychometrics and Algesimetry Panel, which had met 11
times since the start of the Action in 2011. The panel
consisted of a multidisciplinary team with expertise in
pain, dementia, psychology, nursing, geriatric medicine
and clinimetrics who contributed to a series of consensus
meetings conducted in person. This panel was constantly
interacting with other panels responsible for usability,
clinical and experimental validation and reliability testing
and consideration of special situations like end of life care.
This approach focused on theoretically and empirically
extracting and refining pain assessment items to develop a
meta-tool based on the evidence base.Review strategy
The panel scrutinised all included tools. Each assessment
item was pooled to create an assessment database. This
followed a three step reduction process. First, each item
was allocated to the six domains published by the AGS
[16]and the frequency with which each individual assess-
ment item appeared in the total pool was recorded to
provide an indication of the representation of each item in
existing validated scales. Items with a frequency of two and
more automatically qualified for further consideration.
Items with a frequency of less than two were included if
they were derived from an instrument with robust
published evidence of the instrument? s development and
validation (such as ? empty gaze? from DOLOPLUS2). This
process informed the subsequent consensus process to
ensure consideration of the relative importance and use of
specific item types. Second, the item pool was refined to
remove repetitions. Finally, items were further categorised
according to expert consensus within three main categories
of the AGS guidelines ? facial expression, vocalisation, and
body movements.
These three AGS guideline domains were selected for
further scrutiny by expert panel consensus as they were
considered to be the most relevant, building on previous
research regarding pain behaviour, and aspects coveredby other assessment tools. The remaining three domains
(interpersonal interactions, changes in patterns or rou-
tines and change in mental status) were excluded from
the main tool for two key reasons. Firstly, a number of
the items from domains four, five and six that were con-
sidered most relevant to cognitive impairment, such as
aggression, resistance to care and confusion were already
represented in domains one, two and three. An example
of this was restlessness, which fulfilled both categories of
body movement (AGS Domain 3) and changes in activity
patterns or routines (AGS Domain 5). Secondly, it was
felt that a number of pain-related behaviours within the
excluded domains were more broadly symptomatic of
dementia and so might unnecessarily reduce the specifi-
city of the tool itself. For example, changes in appetite
and insomnia commonly arise as part of the progression
of dementia and are not specific to pain and AGS Do-
mains one, two and three. Items within the fourth, fifth
and sixth AGS domains were therefore excluded from
the main meta-tool, but planned for inclusion within the
future overall toolkit through existing measures, for
example to assess BPSD and mood.Identification of candidate pain assessment items for the
PAIC tool
The full membership of the COST Action TD 1005 expert
panels oversaw the selection of pain assessment items for
inclusion in the preliminary draft of the Pain Assessment
in Impaired Cognition (PAIC) tool, under the governance
of the Psychometrics and Algesimetry panel. First, each
panel was consulted on the output of the review strategy
described above to form a second consensus and refine-
ment process. Informed recommendations collated by the
chair of each panel resulted in the creation of subcategor-
ies within each category described above to ensure that
they covered a broad perspective within each. At least one
item from each sub-category was included in the draft
PAIC tool.These subcategories provided structure for the
item reduction process to ensure critical areas were not
excluded and to provide an accurate view of the coverage
and breadth of the items as they were refined. This
process also strengthened the empirical approach taken in
this study. Decisions to include items were guided by pub-
lished evidence of use and indication of ability to capture
pain in addition to the panel? s expert opinion regarding
their clinical utility and accuracy in pain detection.
Scoring systems utilised in each tool were recorded and
evaluated. The combined expertise of the panel informed
the identification of systems that best balanced usability
with psychometric precision. Clear definitions of each
item and instructions for use were created by the expert
panel and preserved for accuracy through consultation
with native English speakers.
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Identification of pain assessment tools
Nine reviews of pain assessment tools were identified
[15,19-26]. A further two reviews were identified in the
updated search [7,13]. Scrutiny of these reviews identi-
fied 12 tools fulfilling the eligibility criteria which were
also agreed through expert consensus with the Working
Groups in the EU-COST action. The included assessment
tools were the ABBEY Pain Scale [27], ADD [28,29], CNPI
[30,31], DS-DAT [32,33], DOLOPLUS-2 [34], EPCA-2 [35],
MOBID-2 Pain Scale [14,36], NOPPAIN [37], PACSLAC
[38], PAINAD [39], PADE [40], and PAINE [41] (Table 3,
see Additional file 1). Following scrutiny of the available
validation data and discussion of clinical utility the panel
agreed that no one tool showed the required feasibility and
level of evidence of reliability, validity and responsiveness
or showed full, appropriate clinical utility.
Categorisation and refinement of assessment items
Item identification, frequency scoring and categorization
were completed for all included scales. Expert consensus
was reached regarding item selection. The panel agreed
that items within AGS domains 1? 3 (Facial expression,
Vocalization and Body movements) were the most
promising for further exploration. The panel agreed to
explore the use of existing validated tools for assessment
of AGS domains four, five and six, which will form part
of the future toolkit. The facial expression category was
divided into the subcategories cognition, emotion, ana-
tomical orientation, autonomic reaction and qualitative
judgment of expression. For example, the cognition sub-
category was created to define the items ? empty gaze ?
and ? seeming disinterested ? , which appeared sufficiently
often as indicative pain behavior in the included scales,
and were agreed within the expert panel to reflect cogni-
tive impairment. The vocalization category consisted of
verbal utterances, nonverbal utterances and breaths, and
the body movement category was split into tension,
defense, pain relieving adjustments and restlessness
(Table 4). Repeated items, or items that overlapped to a
large extent, were removed. A high degree of consistency
and repetition was recorded for each scale. The highest
rate of consistency was within facial expressions items
where 41% of items were found in at least two scales.
Selection of items for inclusion in the PAIC tool
For each of the 12 sub-categories within the domains of
Facial Expression, Body movements and Vocalisation,
the expert panel selected the most promising pain assess-
ment items within each sub-category. Selection was based
on frequency of use of items in published assessment scale
(Table 5). Further selection was then based on interpret-
ation by the expert panel, informed by published labora-
tory and clinical observation and experimental studies,documented response to pain treatment through existing
studies including clinical trials and clinical experience of
the panel.
This process resulted in a final item pool for each of the
12 subcategories within the three domains to be taken
forward for reliability and validity testing in clinical and
experimental settings. A number of items included in the
tool were considered by the panel to be potentially less ac-
cessible to an observer than others, and more dependent
on unsystematic inference. The decision was made to
include these items in the draft tool to enable further
empirical item reduction during the validity and reliability
testing so as to avoid making a-priori assumptions on the
utility of these elements of the tool.
Creation of preliminary draft of the PAIC tool for
experimental and clinical testing
The expert panel came to consensus regarding the
format and scoring structure for each assessment item.
Key factors were ease of use and clarity for the user
regarding the meaning of each score. It was agreed that
at this preliminary stage a graded scoring system would
be taken forward for testing. Based on the literature, a
four-point Likert scale was developed to enable rating of
each item [42,43]. It was agreed that this would produce
a sensitive measure of presence of pain, in addition to
providing a measure of pain intensity. This was consid-
ered to be critical for use in research settings in order to
assess the impact of an intervention on pain. It is there-
fore expected that this format would be used in research
settings. The panel emphasised that for use in clinical
practice a dichotomous response (present/absent) may
support ease of use, particularly in settings such as care
homes where simplicity and usability is a key consider-
ation in implementation. It is expected this simpler format
will be produced following the full evaluation of the scale
prior to dissemination and this will be a focus of future
development. It was recognised that the refinement
needed to create a simple clinical tool may be challenging,
particularly due to the need to retain sensitivity to change
which may be lost if the four-point scale is removed.
Definitive descriptions of each item and instructions for
use of the tool were adapted from the original source tools
through expert panel discussions and through consult-
ation with a native English speaker. The final draft version
of the PAIC tool for validity and reliability testing in
clinical settings is shown in Tables 6, 7 and 8.
Discussion
Pain in dementia is a critical clinical issue which presents
significant challenges for treatment and care. As the num-
bers of people with dementia increase alongside the ageing
population, assessment and treatment of pain in this
patient group will become an increasingly important and
Table 3 Summary of evaluation of included pain assessment scales in published systematic reviews
Stolee
et al. [24]
Zwakhalen
et al. [26]
Herr et al.
[21]
Hadjistavropoulos
et al. [20]
van Herk
et al. [25]
Chapman
et al. [19]
Park
et al. [23]
Lobbezoo
et al. [15]
Herr
et al. [22]
Corbett
et al. [7]
Husebo
et al. [13]
No of scales included
in reviews
10 12 10 11 13 3 11 9 15 12 12
Abbey [27] x x x x x x x X
ADD [28,29] x x x x X X
CNPI [30,31] x x x x x x x x X
DS-DAT [32,33] x X X X X x x x X
DOLOPLUS 2 [34] x X x X x x x x X
EPCA [35] x x X x x X
MOBID-2 [14,36] X X
NOPPAIN [37] x X X x x x x X
PACSLAC [38] X x X X X x X x X
PAINAD [39] x x x x X x x X x X
PADE [40] x x x X x x x x X
PAINE [41] x x X
'x' indicates scale included in the published systematic review; 'X' indicates scales recommended by the review.
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Table 4 Categories of items identified by the expert panel
in domains 1? 3 in the American Geriatric Society guidance
Facial Expression
(AGS domain 1)
Vocalization
(AGS domain 2)
Body movement
(AGS domain 3)
1. Cognition 1. Verbal
utterances
1. Tension
2. Emotional state 2. Nonverbal
utterances
2. Defensive
behaviour
3. Anatomically-based
descriptions
3. Breath 3. Pain relieving
adjustments
4. Autonomic reactions 4. Restlessness
5. Qualitative judgment of
expression
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aims to address this issue by drawing on existing evidence
and leading experts in clinical, professional and academic
fields and by strengthening international collaboration.
The initiative aims to provide an international roadmap to
a better understanding of pain in people with cognitive
impairment and ultimately to improve the assessment of
pain across all treatment settings. This paper describes the
first phase of the collaboration. The objective is to com-
bine evidence from the literature and published pain as-
sessment instruments with clinical and methodological
expertise to reach consensus within Europe on a core as-
sessment tool for pain in people with dementia.
A review of existing assessment tools revealed a num-
ber of potentially useful tools. No one tool showed the
required feasibility and level of evidence of reliability,
validity and responsiveness or showed full, appropriate
clinical utility according to the consensus process, inclu-
sion criteria and expert opinion of the COST Action
panel (Table 3). However, many of the existing tools
identified by the review were based on robust develop-
ment work with some validation data, thus providing a
valuable pool of items from which to build a composite
meta-tool. This is strengthened by the emerging theme
of consistently utilised items across many of the scales,
particularly in facial expressions, which support the
value of this approach. The collaboration has agreed on
the urgent need for one universal user-led pain assess-
ment tool for use with people with dementia in various
clinical and care settings. A key element in the develop-
ment of a new pain assessment tool for dementia was
the need to build on and improve on the existing evi-
dence base and available tools rather than to develop a
tool from scratch, hereby creating a meta-tool. A further
important aim was to create a meta-tool with inter-
national consensus from stakeholders across many Euro-
pean countries in an effort to ensure comprehensive
implementation of the final product. This is a critical
point as a universal assessment tool would enable stand-
ardisation of both clinical practice and assessment inresearch, neither of which are currently possible with
the existing pain assessment tools. Creation of the meta-
tool was achieved through a systematic scrutiny of
current tools to identify the most reliable, frequently
used items for pain assessment followed by close work-
ing with healthcare professionals to ensure clinical utility
from an early stage. Importantly, each decision-making
step within the development of this meta-tool has been
informed by key considerations in pain assessment. Se-
lection of items for inclusion focussed primarily on
measurement of the intensity of pain, with plans to in-
clude additional methods for identifying pain location
and duration in the future full toolkit. This approach,
overseen by an experienced expert panel, has ensured
the meta-tool includes the best items for detection of
pain across the broad spectrum experienced by this pa-
tient group. The panel recognises the potential limitation
to this methodology which centres around the assump-
tion that the key concerns and challenges in assessment
of pain in cognitive impairment have already been recog-
nised. This raises the possibility that issues neglected by
the literature or unrecognised within the panel may not
be incorporated into the work. However, this risk has
been mitigated by ensuring a robust methodology for
the literature review and the broad cross-section of
expertise and experience within the expert panel.
A critical aspect of this work is the unique approach
taken that differentiates the PAIC meta-tool from ap-
proaches taken to develop previous observational scales.
The process did not commence with observation of pa-
tient behavior, but from scrutiny of existing instruments.
The underlying premise is that existing scales are based
on robust, peer-reviewed observational and validation
work conducted by respectable experts in the field, and
thus that a meta-tool can be developed by building on this
documented work and extracting the most relevant parts
of each existing instrument [14,27-41]. It is therefore
important to emphasise that PAIC is a meta-tool due to
its inherited knowledge and evidence-base from existing
instruments. The quality of the meta-tool was ensured by
the systematic selection of instruments from which to
derive items, as described in the methodology.
As a result, all items included in the PAIC meta-tool
are considered to have face validity due to their selection
by the expert panel. Thus, they are included in the
current draft version pending scrutiny at the next stage
of empirical reliability and validity tests. No item will be
excluded until this process is complete, thus maintaining
the integrity of the meta-tool approach. An example of
this is the ? empty gaze? item which, although not immedi-
ately indicative of pain, was included by the expert panel
due to its presence in the DOLOPLUS-2 scale, which has
good validity data. Other items are also included which
may appear to have less specificity for pain, such as
Table 5 Rationale for inclusion of pain assessment items
in PAIC
Frequency of use in
published tools
Item explanation
derived from
published tools
FACIAL EXPRESSION
Pained expression 1 Facial display of pain
Frowning 7 Lowering and drawing
brows together
Narrowing eyes 1 Grimacing, narrowed
eyes with tension
around the eyes
Closing eyes 3 Not just blinking
Raising upper lip 1 Grimacing, upper lip raised,
nose may be wrinkled
Opened mouth 1 The lips are parted, jaw
is dropped
Tightened lips 2 Lips are pressed together
and appear more narrow
Clenched teeth 3 Teeth are pressed together
with tension
Empty gaze 1 Eyes do not reflect any
emotion or thinking activity
(? blank expression? )
Seeming
disinterested
1 Face does not reflect
any interest in the
environment
Pale face 1 Pale skin colour
Teary eyed 5 Watery eyes
Looking tense 3 Facial display of strain
or worry
Looking sad 6 Facial display of
unhappiness, sorrow or low
mood
Looking
frightened
6 Facial display of fear,
alarm or heightened
anxiety
BODY MOVEMENTS
Freezing 2 Tense, sudden stiffening,
rigid, avoiding movement,
holding breath
Curling up 3 Curling up the body tightly,
pulling in arms and legs
Clenching hands 4 Tensing hands, making fists,
grabbing objects tightly
Resisting care 5 Resisting being moved
or resisting care, being
uncooperative
Pushing 2 Actively pushing somebody
or something away
Guarding 7 Protecting affected area,
holding body part, avoiding
touch, moving away
Rubbing 3 Tugging or massaging
affected area
Limping 3 Avoiding pain while
walking in an uneven way
Table 5 Rationale for inclusion of pain assessment items
in PAIC (Continued)
Restlessness 9 Fidgeting, agitation,
rocking back and forth
Pacing 2 Wandering restlessly
back and forth (might
also be in a wheelchair)
VOCALISATION
Using offensive
words
2 Cursing, swearing, or
using foul language
Using
pain-related words
5 Using pain words, like
? ouch? , ? ow? , or ? that hurts
Repeating words 2 Repeating words or
phrases again and again
(not stuttering)
Complaining 3 Expressing being unhappy,
sick, uncomfortable, and/or
in pain
Shouting 1 Using a loud voice to
express words
Mumbling 3 Uttering words and/or
sounds indistinctly
Screaming 4 Using a loud and/or
high-pitched voice to
express sounds
Groaning 10 Moaning, making a deep,
inarticulate sound
Crying 10 Whimpering, sobbing,
wailing, or weeping
Gasping 4 Breathing sharply,
laboriously, and/or loudly
Sighing 3 Taking in and letting
out a long, loud breath
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http://www.biomedcentral.com/1471-2377/14/229anxiety. These apparently non-specific items have been
included following the same rationale, with fidelity to the
meta-tool approach. The further refinement stages will
determine the inclusion of each item in the final version
of the meta-tool, based entirely on the reliability and valid-
ity testing. It is likely that some non-specific items will
succeed in this next stage of refinements since pain does
not always manifest in uniquely specific behaviours. It is
expected that pain-specific items will enable diagnostic
differentiation of pain from other negative states and that
non-specific items such as anxiety will enable a complete
clinical picture of a patient. This highlights the importance
of validating the draft meta-tool to understand what com-
bination of specific and non-specific items are most
valuable.
The PAIC meta-tool will now be translated into at least
seven European languages (German, Dutch, Romanian,
Greek, Norwegian, Spanish, Italian) using the established
Buffalo translation protocol [44]. Translated versions will
then be checked for accuracy using the Think Aloud tech-
nique in which the translation is used in real settings by
Table 6 Pain assessment by observer ratings in PAIC tool: Facial Expressions items*
FACIAL EXPRESSIONS MEANING OF ITEMS Notat all
Slight
degree
Moderate
degree
Great
degree
Not scored
a = Item is not clear
b = Situation is unsuitable
c = Physical status of person
not suitable for scoring
d = Other
Pained expressiona Facial display of pain 0 1 2 3 a b c d
Frowninga Lowering and drawing brows together 0 1 2 3 a b c d
Narrowing eyesc Narrowed eyes with tension around the eyes 0 1 2 3 a b c d
Closing eyesc Not just blinking 0 1 2 3 a b c d
Raising upper lipc Upper lip raised, nose may be wrinkled 0 1 2 3 a b c d
Opened mouthc The lips are parted, jaw is dropped 0 1 2 3 a b c d
Tightened lipsc Lips are pressed together and appear more
narrow
0 1 2 3 a b c d
Clenched teethc Teeth are pressed together with tension in the
jaw
0 1 2 3 a b c d
Empty gazeb Eyes do not reflect any emotion or active
thought ( ? blank expression? )
0 1 2 3 a b c d
Seeming disinterestedb Face does not reflect any interest in the
environment
0 1 2 3 a b c d
Pale faced Pale skin colour 0 1 2 3 a b c d
Teary eyedd Watery eyes 0 1 2 3 a b c d
Looking tensee Facial display of strain or worry 0 1 2 3 a b c d
Looking sade Facial display of unhappiness, sorrow or low
mood
0 1 2 3 a b c d
Looking frightenede Facial display of fear, alarm or heightened anxiety 0 1 2 3 a b c d
*Instructions to users: Please record the appearance of each facial expression described in the table below. Rate the intensity of the expression from ? not at all ? to
? a great degree ? . If an item is not scored please indicate why not.
Subcategories: aemotion, bcognition, canatomical orientation, dautonomic reaction, equalitative judgment of expression.
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address any issues before use (Figure 1). The meta-tool
will then be taken forward for pilot evaluation in clinical
settings to establish the feasibility, reliability and clinical
utility of each item using the COSMIN methodology as a
criterion for psychometric testing [18]. It will also undergo
additional experimental testing to determine its psycho-
metric quality. This will be the first initiative on pain in
impaired cognition to use this approach. The evaluation
will enable refinement of the meta-tool to ensure the final
item set will be based on the empirical, rather than theor-
etical performance of each item in pain assessment. These
data will inform the development of a final meta-tool. Fol-
lowing further refinements a full clinical trial will be con-
ducted in at least three but likely more countries across
settings including hospitals, specialist secondary and pri-
mary care settings and long term care homes. This will
provide a comprehensive dataset of all psychometric prop-
erties of the meta-tool and will ensure that the end result
is of true utility for international use in research and clin-
ical settings. Through the EU-COST initiative additional
theoretical, qualitative and experimental evaluations willbe performed to support the core assessment of the meta-
tool and provide critical insight to inform the final version
and its use.
The inherent strength of this work lies within the col-
laborative approach, which includes representatives from
16 countries. Members include aetiological, experimental
and clinical (geriatric) academics, nurses, physicians, den-
tists, psychologists, physiotherapists and methodological
experts, in addition to individuals with experience of cog-
nitive impairment outside the field of dementia. It is the
first initiative to build on the full library of existing tools,
within the framework of pain assessment published by the
AGS, to create a user-led assessment meta-tool for pain in
dementia and cognitive impairment. We do acknowledge
the potential limitations within the scope of the work,
including the lack of representation from non-EU nations,
particularly the US and Canada. However the EU-COST
collaboration has valuable contacts in key non-member
countries, such as the USA, Canada and Australia, which
will be strengthened during the course of the project. To
date, researchers from the US and Canada have already
been consulted and involved at certain points.
Table 8 Pain assessment by observer ratings in PAIC tool: Vocalisation items*
VOCALIZATION MEANING OF ITEMS Notat all
Slight
degree
Moderate
degree
Great
degree
Not scored
a = Item is not clear
b = Situation is unsuitable
c = Physical status of person
not suitable for scoring
d = Other
Using offensive wordsa Cursing, swearing, or using foul language 0 1 2 3 a b c d
Using pain-related wordsa Using pain words, like ? ouch? , ? ow? ,
or ? that hurts?
0 1 2 3 a b c d
Repeating wordsa Repeating words or phrases again and again
(not stuttering)
0 1 2 3 a b c d
Complaininga Expressing being unhappy, sick, uncomfortable,
and/or in pain
0 1 2 3 a b c d
Shoutinga Using a loud voice to express words 0 1 2 3 a b c d
Mumblinga Uttering words and/or sounds indistinctly 0 1 2 3 a b c d
Screamingb Using a loud and/or high-pitched voice
to express sounds
0 1 2 3 a b c d
Groaningb Making a deep, inarticulate sound 0 1 2 3 a b c d
Cryingb Whimpering, sobbing, wailing, or weeping 0 1 2 3 a b c d
Gaspingc Breathing sharply, laboriously, and/or loudly 0 1 2 3 a b c d
Sighingc Taking in and letting out a long, loud breath 0 1 2 3 a b c d
*Instructions for users: Please record each vocalisation described in the table below. Rate the intensity of each item from ? not at all ? to ? a great degree ? . If an item
is not scored please indicate why not.
Subcategory: averbal utterances, bnonverbal utterances and cbreaths.
Table 7 Pain assessment by observer ratings in PAIC tool: Body Movement items*
BODY
MOVEMENTS MEANING OF ITEMS
Not
at all
Slight
degree
Moderate
degree
Great
degree
Not scored
a = Item is not clear
b = Situation is unsuitable
c = Physical status of person
not suitable for scoring
d = Other
Freezinga Sudden stiffening, avoiding movement, holding breath 0 1 2 3 a b c d
Curling upa Curling up the body tightly, pulling in arms and legs 0 1 2 3 a b c d
Clenching handsa Tensing hands, making fists, grabbing objects tightly 0 1 2 3 a b c d
Resisting careb Resisting being moved or resisting care, being
uncooperative
0 1 2 3 a b c d
Pushingb Actively pushing somebody or something away 0 1 2 3 a b c d
Guardingb Protecting affected area, holding body part,
avoiding touch, moving away
0 1 2 3 a b c d
Rubbingc Tugging or massaging affected area 0 1 2 3 a b c d
Limpingc Avoiding pain while walking in an uneven way 0 1 2 3 a b c d
Restlessnessd Fidgeting, wringing hands, rocking back and forth 0 1 2 3 a b c d
Pacingd Wandering restlessly back and forth
(might also be in a wheelchair)
0 1 2 3 a b c d
Please record the occurrence of each body movement described in the table below. Rate the intensity of the movement from ? not at all ? to ? a great degree ? . If an
item is not scored please indicate why not.
Subcategory: atension, bdefense, cpain relieving adjustments and drestlessness.
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Select Forward Translators (FTs):
2 FTs, native language Dutch, second language English
1 informed (aware of health concept)
1 uninformed (na?ve to concept), with respect to
instrument content
Each BT produces an independent translation of items
from Dutch in English
Each FT produces an independent translation of items
from English in Dutch
Combine translations into one common translation
Select Back Translators (BTs):
2 BTs, native language English, second language Dutch
1 informed (aware of health concept)
1 uninformed (na?ve to concept), with respect to
instrument content
Combine translations into one common translation.
Consult with FT, BT, or both in relation to identified
problems.
For discrepant items repeating forward translation (and
synthesis), back translation, end review until there are no
discrepancies.
Figure 1 The translation process (using English to Dutch as
an example).
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of pain due to the subjective nature of the pain experience
and lack of self-report in people with dementia. This study
has utilised the best available approaches to address this
issue, building on existing tools and utilising the best ob-
servational items for pain assessment to create the PAIC
meta-tool. There is also a key issue regarding the estab-
lished overlap between pain-related and non-pain-related
behaviours, as discussed above, which blur the lines be-
tween pain assessment and other tools for use with people
with dementia. However, this has been clearly recognised.
In addition to the potential inclusion of non-pain specific
items in the final version of the PAIC, the next phase of
the initiative will involve the development of a supporting
toolkit to address the issue.The decision to create a comprehensive toolkit to sup-
port the new meta-tool is an important aspect of this
work. This will provide specific resources to enable assess-
ment of common symptoms of dementia which frequently
overlap with pain-related items. These will particularly
focus on BPSD such as agitation and aggression, as well as
broader measures of function, activities of daily living and
mood. This format will enable users to supplement the
core pain assessment tool and maximise the usefulness of
the overall toolkit. It is also expected that the toolkit will
be tailored for use in different settings and patient groups
such as Huntington? s disease, Parkinson? s disease and
people with learning difficulties or delirium, according to
the unique requirements and challenges these present.
This may include different assessment items or specific
scoring methods. The toolkit will also recognise that while
self-report is usually absent in this patient group, there are
cases where it is possible, for example in early stages of
cognitive impairment. The toolkit will therefore include
simple forms of self-report assessment for use where it is
feasible. Importantly, we hope that a brief version of the
toolkit for use in clinical practice will be created and fully
evaluated alongside the full research tool to ensure that it
will be used in everyday clinical practice. Critical stages of
future work will therefore be in the effective and user-
friendly design of the final toolkit to ensure its ease of use
and suitability in each setting. Key additions will include
considering how to identify the location and duration
(acute vs chronic) of pain, the development of tailored
scales for specific types of pain such as orofacial pain or
back pain and the further consideration of different
types and causes of pain. As a first step, the Orofacial
Pain Scale for Non-Verbal Individuals (OPS-NVI) has
been developed, based on recent pilot work [45]. The
OPS-NVI includes observations of not only facial
expressions, verbalisations & vocalisations, and body
movements, but also of specific orofacial pain-related
behaviours such as limited jaw movements and drool-
ing. Observations are being made at rest, while drinking
and eating, and during oral care. The instrument is cur-
rently at the stage of field testing. Another addition to
the toolkit will include an instrument for the effective
assessment of back pain and neuropathic pain, the
latter is notoriously complex and challenging to detect
in people with cognitive impairment. This issue is of
high clinical relevance and is not well described in the
literature, partly due to the unique assessment and
treatment approaches it requires.
Finally, a dedicated dissemination Working Group will
be essential to oversee an extensive strategy to ensure
the implementation of the final toolkit on an inter-
national basis. This will focus on overcoming the prac-
tical, political and social obstacles to implementation,
incorporating robust translation, communication and
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sations and extensive academic, professional and lay dis-
semination activities.
Conclusions
This EU-COST initiative has employed a previously un-
precedented methodological approach, identifying the
most meaningful pain assessment items based on empir-
ical, rather than theoretical, value, and developing a robust
evaluation and consensus procedure to create a final tool
and toolkit with true universal utility. This paper repre-
sents the first step in this large, multidisciplinary, cross-
cultural initiative to make tangible improvements to the
management of pain in people with dementia across the
EU and further afield.
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